Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 28 Neoplasm Metastasis 9 Neoplasms 8 Brain Neoplasms 5 Triple Negative Breast Neoplasms 3 Recurrence 3 Prostatic Neoplasms 3 Ovarian Neoplasms 3 Neoplasms by Site 3 Glioma 3 Endometrial Neoplasms 3 Breast Diseases 3 Squamous Cell Carcinoma of Head and Neck 2 Liposarcoma 2 Head and Neck Neoplasms 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Spinal Cord Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Kaposi 1 Sarcoma, Ewing 1 Sarcoma 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neurofibromatosis 1 1 Neoplasms, Squamous Cell 1 Multiple Myeloma 1 Meningioma 1 Lymphoma, Non-Hodgkin 1

Interventions

Letrozole 2 ribociclib 1 palbociclib 1 abemaciclib 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × abemaciclib × 90 days × Clear all

NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡